9 Meters Biopharma Inc
OTC:NMTRQ
9 Meters Biopharma Inc
Total Current Liabilities
9 Meters Biopharma Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
9 Meters Biopharma Inc
OTC:NMTRQ
|
Total Current Liabilities
$15.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Liabilities
$54.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Liabilities
$23.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Liabilities
$36.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Liabilities
$28.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Liabilities
$40.1B
|
CAGR 3-Years
33%
|
CAGR 5-Years
26%
|
CAGR 10-Years
17%
|
|
9 Meters Biopharma Inc
Glance View
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 21 full-time employees. The company went IPO on 2016-07-08. The firm is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.
See Also
What is 9 Meters Biopharma Inc's Total Current Liabilities?
Total Current Liabilities
15.6m
USD
Based on the financial report for Mar 31, 2023, 9 Meters Biopharma Inc's Total Current Liabilities amounts to 15.6m USD.
What is 9 Meters Biopharma Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
23%
Over the last year, the Total Current Liabilities growth was 90%. The average annual Total Current Liabilities growth rates for 9 Meters Biopharma Inc have been -1% over the past three years , 23% over the past five years .
